Year Founded
2018
Ownership
Public
Employees
~100
Therapeutic Areas
Infectious DiseasesMetabolic Disorders
Stage
Phase 2
Modalities
Small molecule

Aligos Therapeutics General Information

Clinical stage company with two lead programs: ALG-000184 (CAM-E) for CHB and ALG-055009 (THR-β agonist) for MASH. Recent FDA IND clearance for ALG-000184 and ongoing Phase 2a HERALD study for ALG-055009.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States

Drug Pipeline

ALG-000184
IND
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Aligos Therapeutics's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Aligos Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCFeb 12, 2025$105.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Aligos Therapeutics's complete valuation and funding history, request access »

Aligos Therapeutics Licensing Deals

AssetLicenseeDateTherapeutic Area
MASH oligonucleotidesMerckDec 1, 2020Liver
ALG-055009MerckDec 1, 2020Metabolic
You're viewing 2 of 2 licensing deals. Get the full list »

Aligos Therapeutics Investors

// As per recent $105 million private placement financing Feb 2025—includes new/existing institutional investors but not all are named publicly.[9]
Investor Type: Venture Capital
Holding: Minority
// Known investors from Crunchbase may include Foresite Capital Management LLC etc.
Investor Type: Venture Capital
Holding: Minority